Want to see KMTS full AI Analyst Report?
KMTS Stock Chart & Stats
$25.54
$1.80(8.55%)
At close: 4:00 PM EDT
$25.54
$1.80(8.55%)
Day’s Range― - ―
52-Week Range$17.34 - $30.00
Previous CloseN/A
Volume51.18K
Average Volume (3M)412.84K
Market Cap
$1.63B
Enterprise Value$1.21B
Total Cash (Recent Filing)$198.91M
Total Debt (Recent Filing)$76.45M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Dec 10, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding59,561,794
10 Day Avg. Volume369,156
30 Day Avg. Volume412,838
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.66
Price to Sales (P/S)12.72
P/FCF Ratio-10.38
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue11.38
Enterprise Value/Gross Profit21.12
Enterprise Value/Ebitda-9.29
Forecast
1Y Price Target
$30.00Price Target Upside17.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.45
Revenue Forecast (FY)$140.94M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapid revenue growth, supported by market expansion, share gains, payer coverage and stronger revenue-cycle execution, indicates increasing adoption of Kestra’s cardiac-care platform. If sustained, this scale can improve operating leverage and strengthen the company’s competitive position over the next several quarters.
Gross Margin ExpansionEleven consecutive quarters of sequential gross-margin expansion provides evidence that unit economics are improving through higher revenue per fit, lower cost per fit, volume leverage and cost initiatives. Further expansion would increase the revenue retained to fund commercial investment and reduce losses.
Liquidity And Low LeverageSubstantial liquidity and very low reported leverage give Kestra financial flexibility while it funds commercial expansion, research and development, and operating improvements. This balance-sheet support reduces near-term financing pressure, although it does not yet replace the need for progress toward self-funded operations.
Bears Say
Deep Operating LossesThe scale and persistence of operating losses show that revenue growth has not yet translated into sufficient operating leverage. Continued losses can consume equity and require ongoing financing, while making the path to profitability dependent on margin expansion and disciplined expense growth.
Heavy Cash BurnMaterial negative operating and free cash flow indicate that the business is not currently funding its expansion internally. Persistent cash burn can reduce liquidity over time and constrain investment choices, making execution on revenue growth and cost improvement essential to preserve financial flexibility.
Elevated Operating InvestmentExpense growth is currently outpacing the company’s ability to convert sales into earnings, increasing the risk that strong revenue performance will continue to produce wider losses. Commercial and late-stage R&D spending may support growth, but returns depend on successful execution and future operating leverage.
Kestra Medical Technologies Ltd. News
KMTS FAQ
What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?
Kestra Medical Technologies Ltd. lowest stock price was $17.34 and its highest was $30.00 in the past 12 months.
What is Kestra Medical Technologies Ltd.’s market cap?
Kestra Medical Technologies Ltd.’s market cap is $1.63B.
When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?
Kestra Medical Technologies Ltd.’s upcoming earnings report date is Dec 10, 2026 which is in 48 days.
How were Kestra Medical Technologies Ltd.’s earnings last quarter?
Kestra Medical Technologies Ltd. released its earnings results on Sep 14, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.616 by -$0.134.
Is Kestra Medical Technologies Ltd. overvalued?
According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued.
Does Kestra Medical Technologies Ltd. pay dividends?
Kestra Medical Technologies Ltd. does not currently pay dividends.
What is Kestra Medical Technologies Ltd.’s EPS estimate?
Kestra Medical Technologies Ltd.’s EPS estimate is -0.61.
How many shares outstanding does Kestra Medical Technologies Ltd. have?
Kestra Medical Technologies Ltd. has 59,561,794 shares outstanding.
What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?
Kestra Medical Technologies Ltd. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.616. Following the earnings report the stock price went up 4.655%.
Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?
Currently, no hedge funds are holding shares in KMTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kestra Medical Technologies Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (17.46% Upside)
$30.00 (17.46% Upside)
Blogger Sentiment
Bullish
KMTS Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.44%
12-Months-Change
Fundamentals
Return on Equity
-64.18%
Trailing 12-Months
Asset Growth
30.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kestra Medical Technologies Ltd.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
KMTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly optimistic, with management highlighting 60% year-over-year revenue growth, repeated gross margin expansion, raised fiscal year 2027 guidance, improving payer coverage, commercial share gains, product innovation, and strengthened liquidity. The company also reported larger operating expenses, a wider net loss and adjusted EBITDA loss, and substantial operating cash use, but management characterized these investments and cash trends as part of its growth strategy and expressed confidence in increasing operating leverage and a path to profitability over the next few years.View all KMTS earnings summariesKMTS Stock 12 Month Forecast
Average Price Target
$30.00
▲(17.46% Upside)
Technical Analysis
Ownership Overview
44.00% Insiders
25.95% Mutual Funds
4.58% Other Institutional Investors
18.77% Public Companies and
Individual Investors